Short-wavelength automated perimetry and frequency-doubling technology perimetry in glaucoma

被引:26
作者
Fogagnolo, Paolo [1 ]
Rossetti, Luca [2 ]
Ranno, Stefano [2 ]
Ferreras, Antonio [3 ]
Orzalesi, Nicola [2 ]
机构
[1] GB Bietti Fdn, IRCCS, Rome, Italy
[2] Univ Milan, San Paolo Hosp, Dept Med Surg & Odontoiatry, Eye Clin, Milan, Italy
[3] Miguel Servet Univ Hosp, Dept Ophthalmol, Zaragoza, Spain
来源
GLAUCOMA: AN OPEN WINDOW TO NEURODEGENERATION AND NEUROPROTECTION | 2008年 / 173卷
关键词
glaucoma; standard automated perimetry; short-wavelength automated perimetry (SWAP); frequency-doubling technology perimetry (FDT); matrix; retinal ganglion cells;
D O I
10.1016/S0079-6123(08)01108-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Standard automated perimetry (SAP) is today still the clinical standard for the management of glaucoma and its progression, though it has been shown that it may detect the disease only after the death of a high number of retinal ganglion cells (RGCs). A number of "unconventional" perimetries have recently been evaluated by several clinical studies which showed their ability to identify the earliest glaucoma changes; the most promising of these techniques are short-wavelength automated perimetry (SWAP) and frequency-doubling technology perimetry (FDT). The applicability of these techniques is still limited by a number of factors: the limited economic resources allocated to perimetry; the paucity of well-conducted, prospective longitudinal studies showing the superiority of SWAP and FDT over SAP; and the lack of a consensus on the criteria to define test abnormality with these techniques. The aim of this article is to review the rationale, the limits, and the potentiality of SWAP and FDT for glaucoma management and to summarize the tasks required to improve the clinical usefulness of these two instruments in the future.
引用
收藏
页码:101 / 124
页数:24
相关论文
共 106 条
[31]   Detecting glaucoma with frequency-doubling technology perimetry - A comparison between N-30 and C-20 screening programs [J].
Fogagnolo, P ;
Mazzolani, F ;
Rossetti, L ;
Orzalesi, N .
JOURNAL OF GLAUCOMA, 2005, 14 (06) :485-491
[32]   Lifetime visual disability in open-angle glaucoma and ocular hypertension [J].
Forsman, Eva ;
Kivela, Tero ;
Vesti, Eija .
JOURNAL OF GLAUCOMA, 2007, 16 (03) :313-319
[33]   Glaucoma management among individuals enrolled in a single comprehensive insurance plan [J].
Friedman, DS ;
Nordstrom, B ;
Mozaffari, E ;
Quigley, HA .
OPHTHALMOLOGY, 2005, 112 (09) :1500-1504
[34]  
Gardiner SK, 2006, OPTOMETRY VISION SCI, V83, P432, DOI 10.1097/01.opx.0000225912.06027.ac
[35]  
Girkin CA, 2000, ARCH OPHTHALMOL-CHIC, V118, P1231
[36]  
Gordon MO, 1999, ARCH OPHTHALMOL-CHIC, V117, P573
[37]   What changes can we expect in the brain of glaucoma patients? [J].
Gupta, Neeru ;
Yuecel, Yeni H. .
SURVEY OF OPHTHALMOLOGY, 2007, 52 :S122-S126
[38]   Influence of glaucomatous visual field loss on health-related quality of life [J].
Gutierrez, P ;
Wilson, MR ;
Johnson, C ;
Gordon, M ;
Cioffi, GA ;
Ritch, R ;
Sherwood, M ;
Meng, K ;
Mangione, CM .
ARCHIVES OF OPHTHALMOLOGY, 1997, 115 (06) :777-784
[39]  
Hartline RK, 1940, AM J PHYSIOL, V130, P0700
[40]  
Harwerth RS, 1999, INVEST OPHTH VIS SCI, V40, P2242